Press release
Nutrition & Care
April 4, 2018

Evonik expands cosmetics portfolio with four new active ingredients and adds another technology platform

During in-cosmetics 2018, Evonik will globally present four new active ingredients for skin and hair care. As a common feature, they all share verifiable effectiveness proven by clinical studies and offer the highest degree of sustainability.

Skinolance®, Evonik's first microbiotic skin care product, uses the cell-free lactobacillus extract to promote the natural balance of the skin flora by stimulating the growth of certain beneficial bacteria. This has a positive effect on the barrier function of the skin helping to protect against roughness and dryness. These effects on the skin flora and skin appearance were verified in a clinical study.

“Humans depend on microorganisms, whether in food digestion or for skin protection. Similar to the benefits of probiotic yogurt in the digestive system, microbiotic cosmetic ingredients can have a positive impact on the local microflora of the skin,” says Dr. Tammo Boinowitz, the head of Evonik's Personal Care Business Line. Evonik established the new “Care Biotics” technology platform as the basis for developing additional microbiotic products.

Hairflux® is an affordable ceramide blend for hair and scalp care, which can also be marketed in China (CFDA listing). “For beautiful hair you need a healthy scalp, and Hairflux® acts on both at the same time," says Boinowitz. The olive-based ceramide has a soothing effect on irritated scalps, and makes damaged hair much more resistant due to the gentle manufacturing process that preserves the natural ingredients. The product is suitable for use in hair tonics, care products for the scalp as well as rinses and shampoos for damaged hair.

TEGO® Pep UP, a new tetrapeptide from Evonik, also has a CFDA listing. The active ingredient increases the collagen production of the skin and the fiber production in the extracellular matrix, which results in reduced wrinkle depth and more defined facial contours as visual effects. The product’s lifting effect is of interest for anti-aging and other formulations.

Evonik will also present TEGO® enlight, a product developed for natural skin brightening. It contains a phytic acid salt obtained from rice bran and an extract of white mulberry fruit. Both components have brightening properties that complement each other favorably, and the product can be used for the treatment of age spots, and for general skin brightening.

These product innovations from Evonik will be on display at stand H 20 during in-cosmetics. Skinolance® will also be presented as part of the technical seminar program on April 18 at 2:20 PM.








About Evonik
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.5 billion in 2017.

Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.